We have located links that may give you full text access.
Comparative Study
Journal Article
Review
Comparative properties of various beta-blockers, with an outlook to the future.
Several beta-adrenoceptor blockers with various ancillary properties besides beta-receptor blockade are now available for clinical use. In the treatment of hypertension, angina pectoris, and certain types of cardiac arrhythmia the therapeutic benefit is mediated by beta 1-receptor blockade, whereas the blockade of beta 2-adrenoceptors does usually not contribute to the therapeutic efficacy and is rather associated with adverse reactions. Accordingly, all properties other than beta 1-adrenoceptor blockade should be considered as ancillary properties. The following properties of beta-blockers and the therapeutic relevance of these properties are to be discussed, together with pertinent examples of the drugs involved: beta 1-receptor selectivity and the degree of beta 2-receptor blockade; intrinsic sympathomimetic activity (ISA); duration of action (to be discussed in connection with the pharmacokinetic properties in Prof. Borchard's presentation); lipophilicity, brain penetration and CNS side effects, and cardioprotective properties (secondary prevention following myocardial infarction). Most of these properties have been investigated in full detail and a wide variety of compounds possessing one or more of these properties have been introduced. With respect to the future, beta 1-adrenoceptor selectivity remains an interesting issue, although it is difficult to imagine that compounds which are even more beta 1-selective than bisoprolol can be developed. The cardioprotective activity of beta-blockers deserves further investigations, in particular with respect to the underlying mechanisms. Finally, many new beta-blockers are now becoming available with an additional vasodilator component which may be caused by different mechanisms, like 'direct' vasodilation, beta 2-receptor agonism, alpha-adrenoceptor blockade, or angiotensin-converting enzyme inhibition. The various mechanisms and possible clinical relevance will be discussed.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app